Fortrea Holdings Business Summary

Fortrea Holdings Inc. (FTRE) operates as a leading global contract research organization (CRO) providing comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company generates revenue primarily through service fees and pass-through reimbursements derived from long-term contracts with pharmaceutical, biotechnology, and medical device companies. Its business is structured into two primary segments: Clinical Development, which manages large-scale global trials and functional service provider (FSP) models, and Patient Access, which provides market access strategy and hub services to ensure therapy delivery. Fortrea competes directly with industry giants such as IQVIA, ICON plc, and PPD (Thermo Fisher Scientific), positioning itself as a pure-play, agile alternative that leverages the 30-year legacy of its predecessor, Labcorp’s Clinical Development business, to capture mid-market and large-scale biopharma spend. Following its 2023 spin-off from Labcorp, Fortrea is currently led by CEO Anshul Thakral, who joined in August 2025 after serving as the co-founder and CEO of Launch Therapeutics and holding senior roles at IQVIA. The executive team includes CFO Jill McConnell, a veteran of the Labcorp-Covance transition, and COO Mark Morais, who oversees global clinical development operations. Technology and data strategy are directed by CIO Alejandro Martinez-Galindo, formerly of General Motors and Walgreens. The board is chaired by Peter Neupert, an Operating Partner at Health Equity Strategies, and includes notable directors such as Dr. Amrit Ray, former CMO of Pfizer and Johnson & Johnson. The company maintains high institutional backing, with major stakeholders including Vanguard Group and BlackRock, reflecting its status as a critical infrastructure provider in the life sciences ecosystem.